Blood circulation pressure management may gradual cognitive decline in PD By Liam Davenport.

Certified from medwireNews with authorization from Springer Health care Ltd. All privileges reserved. Neither of the ongoing celebrations endorse or suggest any commercial products, services, or equipment.. Blood circulation pressure management may gradual cognitive decline in PD By Liam Davenport, medwireNews Reporter Cognitive dysfunction in Parkinson’s disease is associated with neurocirculatory abnormalities such as for example orthostatic and supine hypertension, suggesting early treatment of such abnormalities may gradual cognitive decline, say researchers. Joong-Seok Kim, from the Catholic University of Korea, in Seoul, and co-workers performed a comprehensive group of neuropsychologic checks, recorded orthostatic vital signals and ambulatory 24-hour blood circulation pressure, and obtained mind magnetic resonance scans, for 87 individuals with early PD.Additionally Ardelyx is likely to commence a Phase 2b medical trial in the 4th quarter of this yr to evaluate the perfect dosing program for tenapanor for the treating hyperphosphatemia in dialysis patients. Related StoriesAmgen, Xencor partner to develop and commercialize new therapeutics for malignancy immunotherapy, inflammationNew $6.7 million project aims to help kidney dialysis patients live longerIsis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis By regaining the worldwide rights to tenapanor, we now have a late-stage clinical asset which has demonstrated significant guarantee for the treatment of IBS-C and hyperphosphatemia, both of which are conditions where we believe tenapanor could potentially transform the treatment paradigm, said Mike Raab, President and CEO.